Opus Genetics IRD Cash Acquired in Excess of Payments to Acquire Business
Cash Acquired in Excess of Payments to Acquire Business at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness.
The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's cash acquired in excess of payments to acquire business.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's cash acquired in excess of payments to acquire business?
- Opus Genetics (IRD) reported cash acquired in excess of payments to acquire business of $0 in Q4 2025.
- How has Opus Genetics's cash acquired in excess of payments to acquire business changed year-over-year?
- Opus Genetics's cash acquired in excess of payments to acquire business decreased by 100.0% year-over-year, from $302.5K to $0.
- What does cash acquired in excess of payments to acquire business mean?
- Indicates the net cash benefit realized when the cash balance acquired through a business combination exceeds the total consideration paid for the acquisition. This is a rare indicator of a bargain purchase or highly efficient capital deployment in M&A activities.